image: The researchers' anti-integrin therapy using the approved medication vedolizumab (VDZ) reduced aggregates of immune cells (green) in intestinal biopsies from a patient with HIV and IBD. This material relates to a paper that appeared in the Oct. 3, 2018, issue of Science Translational Medicine, published by AAAS. The paper, by M. Uzzan at Icahn School of Medicine at Mount Sinai in New York, NY, and colleagues was titled, "Anti-a4ß7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals." view more
Credit: M. Uzzan <i>et al., Science Translational Medicine </i>(2018)